key: cord-0881350-7nvwwjko
authors: Li, Yang; Ma, Ming-liang; Lei, Qing; Wang, Feng; Hong, Wei; Lai, Dan-yun; Hou, Hongyan; Xu, Zhao-wei; Zhang, Bo; Chen, Hong; Yu, Caizheng; Xue, Jun-biao; Zheng, Yun-xiao; Wang, Xue-ning; Jiang, He-wei; Zhang, Hai-nan; Qi, Huan; Guo, Shu-juan; Zhang, Yandi; Lin, Xiaosong; Yao, Zongjie; Wu, Jiaoxiang; Sheng, Huiming; Zhang, Yanan; Wei, Hongping; Sun, Ziyong; Fan, Xionglin; Tao, Sheng-ce
title: Linear epitope landscape of the SARS-CoV-2 Spike protein constructed from 1,051 COVID-19 patients
date: 2021-03-12
journal: Cell Rep
DOI: 10.1016/j.celrep.2021.108915
sha: 585861e2a57dfdd9ec5d85e6680922faa5d21006
doc_id: 881350
cord_uid: 7nvwwjko

To fully decipher the immunogenicity of the SARS-CoV-2 Spike protein, it is essential to assess which part is highly immunogenic in a systematic way. We generate a linear epitope landscape of the Spike protein by analysing the serum IgG response of 1,051 COVID-19 patients with a peptide microarray. We reveal two regions rich in linear epitopes, i.e., CTD and a region close to the S2’ cleavage site and fusion peptide. Unexpectedly, we find that the RBD lacks linear epitope. We reveal that the number of responsive peptides is highly variable among patients and correlates with disease severity. Some peptides are moderately associated with severity and clinical outcome. By immunizing mice, we obtained linear-epitope-specific antibodies; however, no significant neutralizing activity against the authentic virus was observed for these antibodies. This landscape will facilitate our understanding of SARS-CoV-2-specific humoral responses and might be useful for vaccine refinement.

J o u r n a l P r e -p r o o f protein but not for the RBD. Interestingly, 414-4 binds S1-97 with high affinity, 248

indicating the epitope that 414-4 recognizes is near aa577-588. 249 Actually, the 3 immunogenic epitopes, S1-76, S1-77 and S1-78, were also identified in 250 other related studies (Wang et al., 2020b; . These three epitopes are 251 consecutive and located in the RBM region, which at least partially overlaps with or is 252 close to the binding epitopes of a variety of SARS-CoV-2 neutralizing antibodies, e.g., 253

B38 (Wu et al., 2020d) , CB6 (Shi et al., 2020) and P2B-2F6 (Ju et al., 2020) . To further 254 illustrate these epitopes' locations, we mapped them to the 3D structure of the Spike 255 protein in both the open state and the closed state (Fig. 4C) . In the closed state, 256 aa455-465 of S1-76/77/78 is located in the contact area among the three monomers and is 257 probably difficult to access, aa452-454 and 473-474 form the β-strand and are covered 258 but could be accessed from both sides, and only aa466-472 is exposed and present as a 259 flexible sequence ( Fig. 4D and Fig. S4) . In the open state of the Spike protein, all 260 residues of S1-76/77/78 are exposed and highly accessible (Fig. S4) . To further analyse 261 the immunogenicity of S1-76/77/78, we examined all the available neutralizing 262 antibody-RBD complexes by the end of November 30th, 2020 as far as we know. (Table  263   S7 residues within S1-76/77/78. For the CB6-RBD complex, there are several residues 275 within S1-76/77/78 that directly interact with the following antibodies: Y453, L455, F456, 276 R457, K458, S459, N460, Y473 and Q474. The same interaction residues between 277 neutralizing antibodies and the RBD can also be found in the CV30-RBD, CC12.1-RBD 278 J o u r n a l P r e -p r o o f and C105-RBD complexes (Table S7) . Partial interaction residues of the CB6-RBD 279 complex between S1-76/77/78 can also be found in the REGN10933-RBD, 280 H11-D4-RBD, Fab-2-4-RBD, Ty1-RBD and MR107-RBD complexes, and some other 281 residues, such as L452, T470 and I472, can be found in some of these structures (Table  282 S7). For the P2B-2F6-RBD complex, the only residue that directly interacts with the 283 antibody is L452. In summary, most of these neutralizing antibodies interact with 284 residues located in S1-76/77/78, residues 452-460 and 470-474 play direct roles in the 285 interactions, and the flexible loop consisting of residues 461-469 is irrelevant to these 286 neutralizing antibodies. 287

Broad neutralizing antibodies and a vaccine effective for SARS-CoV-2 and other 288 human coronaviruses are of high interest . We performed a homology 289 analysis for S1-76/77/78 among SARS-CoV-2, the other 6 human coronaviruses, and bat 290 coronavirus BtCoV-RaTG13 (Zhou et al., 2020b) . High homologies were observed for 291 the all 3 epitopes among SARS-CoV-2, SARS-CoV and BtCoV-RaTG13 while low 292 homology level with MERS-CoV and other common coronavirus ( Figure 4E ). The high 293 homology indicates that antibodies elicited by S1-76/77/78 may at least be effective for 294 both SARS-Cov-2 and SARS-CoV. 295

These results strongly suggest that the RBD is rich in conformational epitopes, while it 296 lacks linear epitopes. The underlying mechanism is worth further investigation. 297

CTD is rich in linear epitopes 299

The first "hot" region of linear epitopes is CTD. The whole domain is densely covered by 300 linear epitopes (Fig. 5A) . According to the selection criteria, 6 highly immunogenic 301 epitopes, S1-93, S1-97, S1-105/106, S1-111 and S1-113, were identified. These epitopes 302 are nearly evenly distributed across CTD. We then asked whether these 6 highly 303 immunogenic epitopes were also revealed in other studies. It showed that S1-93 was 304 identified by ReScan (Zamecnik et al., 2020) (Table S3) , as well as COVIDep (Ahmed et 305 al., 2020), S1-97 by ReScan, and S1-111 by COVIDep. 306 S1-93 and S1-97 are located at CTD1, while aa555-564 of S1-93 and aa578-584 of 307 S1-97 are present at the loop region and on the surface of the trimeric Spike protein. 308 S1-105, S1-106, S1-111, and S1-113 are located at CTD2; S1-105/106 are almost at the 309 J o u r n a l P r e -p r o o f loop and present on the surface; S1-111 is at β-strand and the loop but buried inside; and 310 only aa667-669 on the loop region could be accessed. S1-113 is near the S1/S2 cleavage 311 site. Although aa677-684 is invisible in the Spike protein structure, these residues could 312 be exposed on the surface and induce an antibody response to prevent S1/S2 hydrolysis 313 (Fig. 5B) . S1-113 is also on the outer surface, while S1-111 is on the inner surface, and 314 the underlying mechanism by which S1-111 triggers a strong IgG reaction in many 315 patients is worth further study. 316

Homology analysis was performed for the 6 highly immunogenic epitopes (Fig. 5C) . 317

Except for S1-113, high homologies were observed for all 5 epitopes among 318 SARS-Cov-2, SARS-CoV and BtCoV-RaTG13 while lower homology levels were 319

shown among SARS-CoV-2 and MERS-CoV and the other four common coronaviruses. 320

The high homology indicates that antibodies elicited by S1-93, S1-97, S1-105 and S1-111 321 may be effective for both SARS-Cov-2 and SARS-CoV. Additionally, an antibody 322 targeting S1-113 may be specific for SARS-CoV-2. 323

The D614G mutant is the current dominant strain in Europe (Korber et al., 2020) , 324 which has about a 9 times higher infection efficiency in cell assays than that of the 325 wild-type strain (Zhang et al., 2020b) . D614 is within S1-102, an epitope of moderate 326 immunogenicity, and close to the highly immunogenic S1-105. Blocking the D614 region 327 may cause a functionally significant effect. 328

The second epitope hot region spans aa770-829, covering the S2' cleavage site and 330

The second region with highly enriched linear epitopes spans aa770-829 (Fig. S5A) . 332

According to the selection criteria, 6 highly immunogenic epitopes were obtained: S2-15, 333 S2-16, S2-18, S2-19, S2-22 and S2-23. 334

It is interesting to see whether these 6 highly immunogenic epitopes were also 335 identified in related studies. We revealed that S2-22 was identified by a peptide 336 microarray study (Wang et al., 2020b) . Other highly immunogenic linear epitopes 360

Except for the immunogenic epitopes that belong to the RBD and the two "hot" regions, 361 there are other highly immunogenic epitopes dispersed across the Spike protein ( Fig.  362 S6A). S1-5 is located at NTD, and part of the residues, i.e., aa28-31, form the β-strand 363 and are on the surface of the trimeric Spike protein. aa32-36 forms a loop and is partially 364 covered by the other region. S2-78, S2-96 and S2-97 are located in unobserved regions in 365 the C-terminus of the Spike protein. We applied a modelling structure to present these 366 unobserved regions (Fig. S6B) . S2-78 is predicted to be an α-helix, and S2-96/97 is 367 predicted to be a loop. S2-96/97 are at the very C-terminal end of the Spike protein ( Fig.  368 S6B), which is located in the cytoplasm of the host cell. 369

We checked whether these 4 highly immunogenic epitopes were also revealed in other 370 studies. We found that S1-5 was identified by a peptide microarray study (Wang et al., 371 2020b ). S2-78 was identified by ReScan (Zamecnik et al., 2020) , and 3 epitopes (S2-78, 372 S2-96, S2-97) were predicted by COVIDep (Ahmed et al., 2020) . The functional role of 373 S1-5-specific antibodies may be worth further investigation. S2-78 is adjacent to HR2, 374 and the antibody targeting this site may block the conformational change that is essential 375 for effective virus-cell fusion (Liu et al., 2004) . It is surprising to see the high 376 immunogenicity of S2-96 and S2-97 since they are at the very C-terminal end of the 377 Spike protein and theoretically localize in the cytoplasm. Further study is necessary to 378 explore the underlying mechanism and functional roles of these epitopes. Table S2 , longitudinal sera samples were collected. We 389 define collection_time as the days from symptom onset to sample collection, and the 390 collection_time is widely distributed from 1 to 60 (Fig. S7A) . There are > 20 391 samples/day for collection_time ranging from 12 to 54 days, and > 50 samples/day for 392 collection_time ranging from 20 to 45 days. To fully understand the trend dynamics in 393 the IgG to the significant epitopes, the median signal intensities and response frequencies 394 of the epitopes were calculated and plotted according to the collection_time. The S1 395 protein was included as a reference for this analysis. Surprisingly, while S1 IgG slowly 396 decreases when collection_time is approximately 40 days (Fig. 6A) , the antibodies 397 against most of the epitopes dramatically decrease when collection_time is approximately 398 30 days (Fig.6C-G) . However, for the antibodies against S2-78, the linear epitope of the 399 highest frequency, no significant decrease was observed for both the median signal 400 intensity and the response frequency (Fig. 6B) . This result is similar to that for S1 (Fig.  401   6A) . Consistently, the trend in the median number of responsive epitopes is similar to that 402 of the S1 protein (Fig. S7B, C) . These observations suggest that a decrease in or 403 disappearance of the antibodies against some epitopes may contribute to a decrease in S1 404

IgG antibodies, while the antibodies against some other epitopes could last longer. investigate the potential to elicit a neutralizing antibody using significant epitopes, the 414 most physiologically relevant method is to enrich specific antibodies from COVID-19 415 sera using the significant epitopes and then run a neutralization assay . 416

However, for antibody enrichment, a large volume of each serum sample is required, and 417 it is extremely difficult to collect more COVID-19 samples in large volumes at this time. 418

Alternatively, we tested whether the significant linear epitopes could elicit neutralizing 419 antibodies in a mouse model. When selecting overlapping peptides, we chose one with a 420 higher response frequency, except when both peptides were of a high response frequency. 421

For example, S1-78 was selected to represent the RBD. In total, 14 peptides were 422 selected. The peptides were conjugated to KLH, and 3 mice were immunized for each 423 peptide (Fig. 7A) . Most of the linear epitopes elicited specific antibodies (Fig. 7B) . Next, 424

we performed neutralization assays on the authentic SARS-CoV-2 virus with sera 425 collected from the immunized mice. Our results showed that some sera have marginal 426 neutralization activities (Fig. 7C, D) while no neutralization activity was observed for the 427 rest of the sera. The antibodies generated by S1-78, which is located squarely in the RBM 428 region, recognize the RBD protein (Fig. 7B) and are assumed to have high neutralization 429 activity. Unfortunately, significant neutralization activity was not observed, suggesting One limitation of this study is that only short peptides were involved. Though linear 442 epitopes are nicely represented, conformational epitopes may not be. For example, for the 443 RBD region, which is highly immunogenic, only 3 linear epitopes of moderate 444 immunogenicity were identified. To overcome this limitation, one method is to 445 synthesize longer peptides, which may retain some conformational information (Zhang et 446 al., 2020a) . It is necessary to note that for the linear epitopes we identified, they are 447 highly physiologically relevant as all of them were revealed through analysing sera from 448 COVID-19 patients. 449

Our study presents the first IgG linear epitope landscape of the Spike protein, which 450 could only be achieved by analysing a large cohort of samples using a systematic 451 approach, such as the full-coverage peptide microarray of the Spike protein. According to 452 the landscape, it is obvious that the Spike protein is highly immunogenic, there are many 453 epitopes on the protein, and these epitopes are not evenly distributed across the Spike The signal intensities of 1,051 COVID-19 sera against 197 peptides were obtained by 516 using the peptide microarray. The peptides are listed in the X-axis and aligned to the 517 corresponding locations on the Spike protein. As a control, the signal intensities of the S1 518 protein were also presented. The missing spots are peptides that either could not be 519 synthesized or failed the BSA conjugation (see Table S1 for details). A cohort of 528 520 control sera were also analysed on the microarray. In addition, the known 521 N-glycosylation sites (N-glyco) were aligned with the Spike protein. The peptides or 522 regions with significant binding were marked blue. Peptide S1-88 was specifically 523 labelled because significant bindings were also observed for the controls. and severe (non-survivors) for the S1 protein (E), S1-93 (F), S1-97 (G), and S2-78 (H). 553

The data were presented using the median with interquartile for the upper part, and 554 response frequency with a 95% confidential interval for the lower part. P values were 555 calculated using the two-sided t-test for the upper part and the χ 2 test for the lower part 556 (PDB ID: 6X6P). Specifically, S1-93, aa553-564, red; S1-97, aa577-588, blue; 574 S1-105/106, aa625-642, yellow; S1-111, aa661-672, green; and S1-113, S1-113, 673-684, 575 orange. C. Homology analysis of the significant epitopes s among the 7 known human 576 coronaviruses and bat coronavirus BtCoV-RaTG13. Amino acids with 577 consistencies >=50% among the 8 coronaviruses are marked in red, and the loop, α-helix 578 and β-strand region are shown as a line, a coil and an arrow above the sequences, 579

respectively. An unobserved structure is shown as a dotted line. 

Further information and requests for resources and reagents should be directed to and will 602 be fulfilled by the Lead Contact, Sheng-ce Tao For the plaque reduction neutralization test, Vero E6 cells were grown to confluence in a 691 12-well plate (Corning, USA) at 37°C, 5% CO 2 , overnight. Additionally, 300 µL twofold 692 serial diluted serum samples from 1:10 to 1:80 were prepared in 2.5% FBS-DMEM. The 693 live SARS-CoV-2 virus (300 PFU/mL) was added into the serum at a 1:1 volume, mixed 694 completely, and incubated at 37°C for 1 h. Then, cell culture media were removed from 695 the 12-well plates, and 500 µL of serum-virus mixture was added to each cell. After 696 incubation at 37°C for 1 h, the mixture was replaced with 1000 µL 2.5% FBS-DMEM 697 containing 0.8% carboxymethylcellulose (Sigma-Aldrich, USA). Four days later, the 698 plates were fixed with 8% paraformaldehyde and stained with 0.5% crystal violet. Table S1 . Reactivity of all the peptides on the microarray (related to Figure 1 and 735 Figure S1 ). 736 Table S2 . Serum samples tested in this study (related to Figure 1) . 737 Table S3 . Highly immunogenic epitopes (related to Figure 1) . 738 Table S4 . Epitope map on S protein 3D structures from more resources (related to 739 Figure 1) . 740 Table S5 . Statistical analysis of the IgG responses against the significant epitopes 741 and S1 protein related to gender, age, severity and NAT (related to Figure 3) . 742 Table S6 . Clinical parameters that are correlated with antibody response (related to 743 

Factors in B cell competition and immunodominance

COVIDep: A web-based 755 platform for real-time reporting of vaccine target recommendations for SARS-CoV-2

The 758 proximal origin of SARS-CoV-2

Efficacy and Safety of the 761 mRNA-1273 SARS-CoV-2 Vaccine

SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies

Antibody cocktail to SARS-CoV-2 spike 768 protein prevents rapid mutational escape seen with individual antibodies

Predicting vaccine responsiveness

A single dose SARS-CoV-2 simulating particle vaccine induces potent 774 neutralizing activities

Potent neutralizing antibodies against SARS-CoV-2 identified by 777 high-throughput single-cell sequencing of convalescent patients' B cells

A neutralizing human antibody binds to the N-terminal domain of 781 the Spike protein of SARS-CoV-2. Science (80-. )

Slow Delivery 784 Immunization Enhances HIV Neutralizing Antibody and Germinal Center Responses 785 via Modulation of Immunodominance

Selection, biophysical 788 and structural analysis of synthetic nanobodies that effectively neutralize SARS-CoV-2

An interactive web-based dashboard to track 791 COVID-19 in real time

A systematic 793 review of SARS-CoV-2 vaccine candidates

Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy

Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy

Induction of hepatitis A 799 virus-neutralizing antibody by a virus-specific synthetic peptide

An 802 alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction

Studies in humanized mice and convalescent 806 humans yield a SARS-CoV-2 antibody cocktail

Studies in humanized mice and convalescent 809 humans yield a SARS-CoV-2 antibody cocktail

Prospects for a safe COVID-19 812 vaccine

SARS-CoV-2 S Protein: Biophysical, Biochemical, Structural, and Antigenic Analysis

Clinical features of patients infected with 2019 novel coronavirus in Wuhan , 819 China

Structural basis for potent 822 neutralization of SARS-CoV-2 and role of antibody affinity maturation

Persistence and decay of 826 human antibody responses to the receptor binding domain of SARS-CoV-2 spike 827 protein in COVID-19 patients

Immunological considerations for COVID-19 vaccine strategies

SARS-CoV-2 proteome microarray for global profiling of COVID-19 specific 833 IgG and IgM responses

Neutralizing Antibodies against SARS-CoV-2 835 and Other Human Coronaviruses

Human neutralizing antibodies elicited by SARS-CoV-2 infection

Tracking changes 841 in SARS-CoV-2 Spike: evidence that D614G increases infectivity of the COVID-19 virus

SARS-CoV-2 vaccines in development

A Therapeutic 846 Non-self-reactive SARS-CoV-2 Antibody Protects from Lung Pathology in a 847 COVID-19 Hamster Model

A simple method for displaying the hydropathic 849 character of a protein

Autoantigen discovery 852 with a synthetic human peptidome

Linear epitopes of SARS-CoV-2 spike protein elicit neutralizing antibodies 855 in COVID-19 patients

Longitudinal serum autoantibody repertoire profiling identifies surgery-associated 858 biomarkers in lung adenocarcinoma

Anti-spike IgG causes severe acute lung injury by skewing 861 macrophage responses during acute SARS-CoV infection

Potent neutralizing antibodies against multiple epitopes on 864 SARS-CoV-2 spike

Interaction between heptad repeat 1 and 2 regions 867 in spike protein of SARS-associated coronavirus: Implications for virus fusogenic 868 mechanism and identification of fusion inhibitors

Antibody responses to SARS-CoV-2 in patients with 871 COVID-19

Clinical and immunological assessment of asymptomatic 874 SARS-CoV-2 infections

Structural basis for neutralization of SARS-CoV-2 and SARS-CoV 877 by a potent therapeutic antibody

COVID-19: consider cytokine storm syndromes and immunosuppression

Mapping 883 Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding 884 Domain by Structure-Guided High-Resolution Serology

Structural and functional analysis of 887 a potent sarbecovirus neutralizing antibody

Two linear epitopes on the 890 SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients

Safety and Efficacy of the 894 BNT162b2 mRNA Covid-19 Vaccine

SARS-CoV-2 immunity: 896 review and applications to phase 3 vaccine candidates

The receptor-binding 899 domain of the viral spike protein is an immunodominant and highly specific target of 900 antibodies in SARS-CoV-2 patients

Multivalency transforms 903 SARS-CoV-2 antibodies into broad and ultrapotent neutralizers

An ultrapotent synthetic 907 nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike

A human neutralizing antibody targets the receptor binding site of 911 SARS-CoV-2

Identification of a linear B-cell epitope on glycoprotein (GP) 2a of 914 porcine reproductive and respiratory syndrome virus (PRRSV)

Viral epitope profiling of COVID-19 patients 918 reveals cross-reactivity and correlates of severity

Map of SARS-CoV-2 spike epitopes not shielded by glycans

Ultrapotent human 925 antibodies protect against SARS-CoV-2 challenge via multiple mechanisms

Immunology of COVID-19: Current 929 State of the Science

Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Human IgG cell neutralizing monoclonal antibodies block SARS-935

CoV-2 infection

SARS-CoV-2 proteome microarray for mapping COVID-19 938 antibody interactions at amino acid resolution

SARS-CoV-2 proteome microarray for mapping COVID-19 941 antibody interactions at amino acid resolution

An array of 60,000 antibodies for proteome-scale 945 antibody generation and target discovery

Site-specific glycan analysis of the SARS-CoV-2 spike. Science (80-. ). eabb9983

Broad neutralization of 950 SARS-related viruses by human monoclonal antibodies

Risk Factors Associated With Acute Respiratory Distress Syndrome 953 and Death in Patients With Coronavirus Disease

A new coronavirus associated with human respiratory 957 disease in China

An alternative binding mode of 960 IGHV3-53 antibodies to the SARS-CoV-2 receptor binding domain

A noncompeting pair of human neutralizing antibodies block COVID-19 964 virus binding to its receptor ACE2

Comprehensive serological profiling 967 of human populations using a synthetic human virome

A highly conserved cryptic epitope in the receptor binding domains of 970 SARS-CoV-2 and SARS-CoV. Science (80-. )

Structural basis of a shared antibody response to 973 SARS-CoV-2. Science

ReScan, a Multiplex 976 Diagnostic Pipeline, Pans Human Sera for SARS-CoV-2 Antigens

Mining of epitopes on spike protein of SARS-CoV-2 from 980 COVID-19 patients

The D614G mutation in the SARS-CoV-2 spike protein reduces S1 983 shedding and increases infectivity

The Manganese Salt (MnJ) Functions as A Potent Universal Adjuvant

Structural basis for the 989 neutralization of SARS-CoV-2 by an antibody from a convalescent patient

A pneumonia outbreak associated with a new coronavirus 993 of probable bat origin

construct a B cell linear epitope landscape of SARS-CoV-2 spike protein, based on a large cohort of COVID-19 patients. The epitope responses were related to disease severity and outcome but mainly elicit non-neutralizing antibodies

Highlights • A linear epitope landscape of the SARS-CoV-2 Spike from 1